Vulvovaginal candidiasis treatment granted FDA QIDP and Fast Track designations

New Jersey based biotechnology company, SCYNEXIS, Inc. announced this week that the U.S. Food and Drug Administration(FDA) has granted both Qualified Infectious Disease Product (QIDP) and Fast Track designations for the oral formulation of SCY-078, SCYNEXIS's novel oral and intravenous antifungal agent, for the treatment of vulvovaginal candidiasis (VVC) and for the prevention of recurrent VVC. Additionally, SCYNEXIS announced it has ["]

The post Vulvovaginal candidiasis treatment granted FDA QIDP and Fast Track designations appeared first on Outbreak News Today.